智通财经网·2026-01-20 09:54Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for its self-developed B023 cell injection, marking a significant advancement in innovative biopharmaceuticals targeting late-stage or metastatic solid tumors that are not amenable to surgery [1] Group 1: Product Development - B023 cell injection is classified as a Class I innovative biopharmaceutical, specifically designed for patients with locally advanced or metastatic solid tumors that have failed standard treatments and lack effective therapeutic options [1] - The core component of B023 is invariant natural killer T (iNKT) cells, which are a type of non-classical T cell with a constant T cell receptor (TCR) that can be applied universally without causing graft-versus-host disease (GvHD) [1] - The project has been entirely developed by Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., and the company holds complete intellectual property rights for the product [1] Group 2: Financial Investment - As of the date of the announcement, the total research and development investment for the B023 project has reached approximately 39.2584 million RMB [1] - There are currently no other products with the same indication and type available in the global market, highlighting the uniqueness of B023 [1]